AbbVie announced the U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen for Skyrizi (risankizumab-rzaa) for adults with moderately to severely active Crohn’s disease (CD)…. read more.
AbbVie announced new findings from the Phase 3 AFFIRM study evaluating a new option for induction treatment with Skyrizi (risankizumab-rzaa) in adults with moderately to severely active Crohn’s… read more.
Eli Lilly and Company announced positive late-breaking one-year results from the Phase 3 SHINE-2 study of Omvoh (mirikizumab-mrkz) in pediatric patients ages 6 to 17 with moderately to… read more.
Palisade Bio, Inc. a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases, announced clinical and translational findings presented in one oral presentation and three moderated posters at… read more.
11th October 2026 – AbbVie announced the presentation of 22 scientific abstracts from its market-leading inflammatory bowel disease (IBD) portfolio at the American College of Gastroenterology (ACG) 2026… read more.
Phathom Pharmaceuticals, Inc. announced the initiation of patient screening in pHalcon-NERD-302, a registrational Phase 3 study evaluating an as-needed (PRN or on-demand) investigational dosing regimen of Voquezna (vonoprazan)… read more.
New research presented at the Association of Anaesthetists Annual Meeting in Liverpool, UK (16-18 September) and published in the Association’s journal Anaesthesia shows that, for patients undergoing surgical… read more.
AbbVie announced that it has submitted an application to the European Medicines Agency (EMA) seeking approval for Skyrizi (risankizumab) for subcutaneous (SC) induction for the treatment of adult… read more.
Patients with inflammatory bowel disease (IBD) face a significantly higher risk of psychiatric disorders starting two to three years before diagnosis and lasting up to a decade after, according to a nationwide… read more.
The American Gastroenterological Association (AGA) today announced the launch of Nigel, an artificial intelligence (AI)-powered virtual assistant developed exclusively for gastroenterology and hepatology. Built using AGA’s trusted clinical guidance and developed in collaboration… read more.
Breast milk helps shape the gut microbiota for longer than previously thought. Researchers from DTU and Rigshospitalet have discovered that sugars in breast milk, which are nondigestible by… read more.
HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces results from the pivotal Phase II registration study of fanregratinib (HMPL-453) in patients with intrahepatic cholangiocarcinoma (“ICC”) will be presented… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
